Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study

IMPORTANCE: Atezolizumab (anti–programmed death ligand 1) has demonstrated safety and activity in advanced and metastatic urothelial carcinoma, but its long-term clinical profile remains unknown. OBJECTIVE: To report long-term clinical outcomes with atezolizumab therapy for patients with metastatic...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:JAMA Oncol
Autori principali: Petrylak, Daniel P., Powles, Thomas, Bellmunt, Joaquim, Braiteh, Fadi, Loriot, Yohann, Morales-Barrera, Rafael, Burris, Howard A., Kim, Joseph W., Ding, Beiying, Kaiser, Constanze, Fassò, Marcella, O’Hear, Carol, Vogelzang, Nicholas J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Medical Association 2018
Soggetti:
Original Investigation
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5885219/
https://ncbi.nlm.nih.gov/pubmed/29423515
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.5440
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi